Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer

Abstract There has been no previous study on the efficacy of the thoracic radiotherapy (TRT) in oligometastatic or polymetastatic extensive stage small-cell lung cancer (ES-SCLC) to the overall survival (OS). In a group of 270 ES-SCLC cases retrospective study, 78 patients (28.9%) had oligometastase...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li-Ming Xu, Chingyun Cheng, Minglei Kang, Jing Luo, Lin-Lin Gong, Qing-Song Pang, Jun Wang, Zhi-Yong Yuan, Lu-Jun Zhao, Ping Wang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5a8801025ff643daa68d35710c63fb73
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5a8801025ff643daa68d35710c63fb73
record_format	dspace
spelling	oai:doaj.org-article:5a8801025ff643daa68d35710c63fb732021-12-02T11:52:57ZThoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer10.1038/s41598-017-09775-02045-2322https://doaj.org/article/5a8801025ff643daa68d35710c63fb732017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-09775-0https://doaj.org/toc/2045-2322Abstract There has been no previous study on the efficacy of the thoracic radiotherapy (TRT) in oligometastatic or polymetastatic extensive stage small-cell lung cancer (ES-SCLC) to the overall survival (OS). In a group of 270 ES-SCLC cases retrospective study, 78 patients (28.9%) had oligometastases and 192 (71.1%) had polymetastases, among which 51 oligometastatic patients (65.4%) and 93 polymetastatic patients (51.6%) received TRT. Propensity score matching (PSM) was utilized. The 2-year OS, progression free survival (PFS) and local control (LC) in oligometastatic and polymetastatic patients were 22.8% and 4.5% (p < 0.001), 12.0% and 3.8% (p < 0.001), and 36.7% and 6.1% (p < 0.001), respectively. The 2-year OS in oligometastatic patients with the chemotherapy + radiotherapy and chemotherapy alone were 25.2% and 12.7% (p = 0.002), in contrast to 10.0% and 6.8% (p = 0.030) in polymetastatic patients. The estimated hazard ratios for survival were 2.9 and 1.7 for both oligometastatic and polymetastatic patients with radiotherapy. The polymetastatic group has a lower LC (6.1% v.s. 36.7%, (p < 0.001)), due to polymetastases patients receiving involved-sites radiotherapy with low dose schemas. TRT improved OS of patients with oligometastases and polymetastases. Our study demonstrated that aggressive TRT might be a suitable addition of chemotherapy when treating ES-SCLC patients with oligometastases and polymetastases.Li-Ming XuChingyun ChengMinglei KangJing LuoLin-Lin GongQing-Song PangJun WangZhi-Yong YuanLu-Jun ZhaoPing WangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Li-Ming Xu Chingyun Cheng Minglei Kang Jing Luo Lin-Lin Gong Qing-Song Pang Jun Wang Zhi-Yong Yuan Lu-Jun Zhao Ping Wang Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer
description	Abstract There has been no previous study on the efficacy of the thoracic radiotherapy (TRT) in oligometastatic or polymetastatic extensive stage small-cell lung cancer (ES-SCLC) to the overall survival (OS). In a group of 270 ES-SCLC cases retrospective study, 78 patients (28.9%) had oligometastases and 192 (71.1%) had polymetastases, among which 51 oligometastatic patients (65.4%) and 93 polymetastatic patients (51.6%) received TRT. Propensity score matching (PSM) was utilized. The 2-year OS, progression free survival (PFS) and local control (LC) in oligometastatic and polymetastatic patients were 22.8% and 4.5% (p < 0.001), 12.0% and 3.8% (p < 0.001), and 36.7% and 6.1% (p < 0.001), respectively. The 2-year OS in oligometastatic patients with the chemotherapy + radiotherapy and chemotherapy alone were 25.2% and 12.7% (p = 0.002), in contrast to 10.0% and 6.8% (p = 0.030) in polymetastatic patients. The estimated hazard ratios for survival were 2.9 and 1.7 for both oligometastatic and polymetastatic patients with radiotherapy. The polymetastatic group has a lower LC (6.1% v.s. 36.7%, (p < 0.001)), due to polymetastases patients receiving involved-sites radiotherapy with low dose schemas. TRT improved OS of patients with oligometastases and polymetastases. Our study demonstrated that aggressive TRT might be a suitable addition of chemotherapy when treating ES-SCLC patients with oligometastases and polymetastases.
format	article
author	Li-Ming Xu Chingyun Cheng Minglei Kang Jing Luo Lin-Lin Gong Qing-Song Pang Jun Wang Zhi-Yong Yuan Lu-Jun Zhao Ping Wang
author_facet	Li-Ming Xu Chingyun Cheng Minglei Kang Jing Luo Lin-Lin Gong Qing-Song Pang Jun Wang Zhi-Yong Yuan Lu-Jun Zhao Ping Wang
author_sort	Li-Ming Xu
title	Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer
title_short	Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer
title_full	Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer
title_fullStr	Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer
title_full_unstemmed	Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer
title_sort	thoracic radiotherapy (trt) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/5a8801025ff643daa68d35710c63fb73
work_keys_str_mv	AT limingxu thoracicradiotherapytrtimprovedsurvivalinbotholigoandpolymetastaticextensivestagesmallcelllungcancer AT chingyuncheng thoracicradiotherapytrtimprovedsurvivalinbotholigoandpolymetastaticextensivestagesmallcelllungcancer AT mingleikang thoracicradiotherapytrtimprovedsurvivalinbotholigoandpolymetastaticextensivestagesmallcelllungcancer AT jingluo thoracicradiotherapytrtimprovedsurvivalinbotholigoandpolymetastaticextensivestagesmallcelllungcancer AT linlingong thoracicradiotherapytrtimprovedsurvivalinbotholigoandpolymetastaticextensivestagesmallcelllungcancer AT qingsongpang thoracicradiotherapytrtimprovedsurvivalinbotholigoandpolymetastaticextensivestagesmallcelllungcancer AT junwang thoracicradiotherapytrtimprovedsurvivalinbotholigoandpolymetastaticextensivestagesmallcelllungcancer AT zhiyongyuan thoracicradiotherapytrtimprovedsurvivalinbotholigoandpolymetastaticextensivestagesmallcelllungcancer AT lujunzhao thoracicradiotherapytrtimprovedsurvivalinbotholigoandpolymetastaticextensivestagesmallcelllungcancer AT pingwang thoracicradiotherapytrtimprovedsurvivalinbotholigoandpolymetastaticextensivestagesmallcelllungcancer
_version_	1718394924807749632

Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer

Ejemplares similares